Thymulin is a well-characterized thymic hormone that exists as a nonapeptide coupled to equimolar amounts of Zn 2+ . Thymulin is known to have multiple biological roles, including T cell differentiation, immune regulation, and analgesic functions. It has been shown that thymulin is produced by the reticulo-epithelial cells of the thymus, and it circulates in the blood from the moment of birth, maintain its serum level until puberty diminishing thereafter in life. To study the localization of this hormone, we prepared polyclonal and monoclonal antibodies against the commercial peptide and utilized immunocytochemical techniques for visualization. The results indicate that thymulin stains the thymic reticular cells, the outer layers of Hassall´s corpuscles and a large round cellular type, which is keratin-negative and does not show affinity for the common leukocyte antigen (CD-45). In mice, this thymulin-positive cell remains in the thymus throughout life and even appears in relatively increased numbers in old involuted thymi. It also appears in thymusdependent areas of the spleen and lymph nodes, demonstrating that at least one of the thymus cells containing this peptide can be found in peripheral lymphoid tissue.
INTRODUCTION
The thymus is the central immunological organ where T cell differentiation and repertoire selection takes place. The thymus microenvironment, influenced by cellular and humoral signals, plays a central role in these events that shape the cellular immune response. Thymic hormones constitute an important part of the humoral thymus milieu, which contributes to T cell differentiation, and selection of T exportable cells to the periphery.
Thymic hormones are known to have pleiotropic roles within the thymic gland and in the periphery, but their immunological importance is not precisely understood. The reason for the lack of knowledge about the thymic factors functions may be, as Stutman proposed, due to research characterized by "passionate intuition" or the "mission oriented attitude" that dominated the field in early studies that sought solutions for health problems of immunodeficiency and autoimmunity (Stutman, 1983) . This approach seems to continue to dominate the field of immunology, as well as other areas of biology research, emphasizing applications for medical problems in humans and economically important animals.
Thymic peptides have been purified and sequenced in the past, and even used in clinical trials. One of these thymic hormones is a well characterized nonapeptide originally isolated from serum by Bach and Dardenne (1972) and named Facteur Thymique Serique (FTS) (1973) . The aminoacid sequence of this peptide is Glu-Ala-Lys-Ser-GlnGly-Gly-Ser-Asn and is produced by reticuloepithelial thymic cells (Dardenne et al., 1974) . The biological activity of this thymic hormone is highly dependent on its molecular spatial conformation, which in turn depends on the metal element bound to its linear structure (Dardenne et al., 1982) . It has been shown that the antigenic characteristics of this peptide and its capacity to induce differentiation in T cells depend on its equimolar association with Zn 2+ , but not with Al 3+ or Cu 2+ that can also bind (Gastinel et al, 1984; Cung et al, 1988) .
The Zn 2+ -peptide complex with full biological activity is known as thymulin (Dardenne et al., 1982) . At present we know that thymulin production is strongly influenced by the neuroendocrine system (Fabris and Mocchegiani, 1985; Dardenne et al., 1989) and that its serum level in humans and other mammals is age-dependent. (Bach and Dardenne, 1972; Bach and Dardenne, 1973; Consolini et al., 2000) . Thymulin is capable of inducing some markers of T cell differentiation (Dardenne et al., 1978; Incefy et al., 1980) , to restore some T cell functions , improve some endocrine parameters (Goya et al, 2007) and recently, it has become clear that this thymic factor possesses important antiinflammatory and analgesic properties (Safieh-Garabedian et al., 1982; Safieh-Garabedian et al., 1983; Dardenne et al., 2006) .
In the present study, we describe the reactivity against different structures of lymphoid organs, of anti-synthetic thymulin polyclonal and monoclonal antibodies prepared in our laboratory. Results demonstrate that this thymic hormone is produced or accumulated, besides the reticuloepithelial thymic cells, in a particular large round cell present in the thymus and in peripheral lymphoid organs like spleen and lymph nodes. This cell, which we have designated as "C1", contains thymulin in cytoplasmic granules and is also present in the lymph nodes of nude and SCID mice, suggesting extrathymic production.
MATERIAL AND METHODS

Obtaining lymphoid tissue
Lymphoid organs obtained from RK mice bred in our facility were used in the majority of the experiments shown here. According the needs of each experiment, Wistar rats were also used for immunization.
Animals were kept under standard conditions with food and water ad libitum. For some experiments, paraffinembedded lymphoid tissue of nude and SCID mice were obtained from the Center for Molecular Medicine and Infectious Disease at Virginia Tech., USA, and paraffinembedded normal human thymus was obtained from the Department of Pathology of the Hospital Regional de Valdivia, Chile.
Preparation of antibodies against thymulin
To produce rat polyclonal antibodies against thymulin, 2 mg of the commercial peptide FTS was mixed with 6 mg of Limulus polyphemus hemocyanin (LPH) (Sigma Chem. Co.) in a total volume of 1 ml 0.1 M, pH 7.4 phosphate buffer. Next, 25 μl of 25% glutaraldehyde was added and the mixture was kept under constant agitation for 12 hrs. The conjugated material was dialyzed against a saline solution, the resulting volume was adjusted to 5 ml and kept frozen until use.
To induce antibody production against the LPH-coupled peptide, the conjugate was emulsified with complete Freund´s adjuvant and injected intradermally in multiple points in the dorsal region of rats. Each animal received 500 ul of the original conjugate. For the booster injection 3 weeks after the primary immunization, the same amount of the conjugate was emulsified in incomplete Freund´s adjuvant and injected subcutaneously. After an additional 3 weeks, the rats received the same dose of antigen alone by intraperitoneal injection, and one week later the rats were bled. The serum was kept frozen until use.
For preparation of monoclonal antibodies, rats immunized as described above received a final booster given intravenously, and 3 days later spleen cells were obtained and fused with the plasmocytoma cell line NSO/2 following the procedure originally described by Koehler and Milstein (1975) , with some modifications established in our laboratory previously described in detail (Villegas et al. 1991) .
Specificity of antibodies against FTS and their capacity to bind thymulin
To test the capacity of the polyclonal and monoclonal antibodies to recognize FTS, the dot-immunobinding technique described by Hawkes et al. (1982) was used as an initial screening. Briefly, the synthetic FTS was conjugated to bovine seroalbumin (BSA) (Sigma Chem. Co, USA), the conjugate was adjusted to a concentration of 20 mg per ml, and 10 ml aliquots of this peptide-carrier complex were seeded on nitrocellulose membranes (MFS, USA). The membranes were dried and subsequently blocked with 0.3% Tween 20 (Sigma Chem. Co.) in PBS for 45 min at 37 °C. Next, the nitrocellulose membranes were incubated for 4 hrs at 37 °C with dilutions of polyclonal rat antibodies or with non-diluted hybridoma supernatants. The membranes were washed three times, incubated with a rabbit anti-rat immunoglobulin produced in our laboratory, and then incubated with the PAP complex. After thorough washing, membrane reactions were visualized by incubation for 10 min with a saline solution containing 0.5 mg diaminobencidine (DAB, Sigma Chem. Co.) and 0.03% of H 2 O 2 (Farmoquímica del Pacífico S.A.). The enzymatic reaction was stopped with distilled water. In all experiments, appropriate positive and negative controls were included. To further determine if the selected hybridoma supernatants secreted antibodies able to recognize thymulin in situ, all dot immunobinding-positive supernatants were tested by immunocytochemistry using human thymus histological sections following the procedure described here.
Histology and immunocytochemistry
The tissue samples were immersed in Bouin's fixative, embedded in histological paraffin and cut into 6-mm sections, unless otherwise noted. Histological sections were stained with hematoxylin-eosin or processed for immunocytochemistry.
The unlabeled enzyme immunocytochemistry method of peroxidase antiperoxidase (PAP) described by Sternberger (1979) was used throughout. Several primary antibodies were tested to characterize thymulin-containing cells. For this purpose, tissue sections were incubated with polyclonal rat or monoclonal rat anti-FTS primary antibodies overnight in a humid chamber at room temperature. In some experiments, rabbit anti-bovine cytokeratin or anti-human neuron specific enolase (Dako Corporation) were used. Primary antibodies were always diluted in 0.05 M tris buffer, pH 7.8. After incubation, tissue sections were extensively washed with phosphate buffer saline (PBS) and incubated for 30 min with the secondary antibody, next the sections were washed and the PAP complex was added. When the primary antibody was rat monoclonal or polyclonal immunoglobulin, we used a monoclonal rat PAP prepared according to Mason et al. (1982) and described elsewhere (Villegas et al., 1991) . After incubation for 30 min with PAP, the sections were washed, and the reaction was revealed with a solution containing 0.2% of 3,3' diaminobenzidine tetrahydrochloride (DAB, Sigma Chem. Co.) in the presence of 0.007% H 2 O 2 (Merck) for 15 min at room temperature. After incubation in DAB, the sections were washed in distilled water, dehydrated, cleared with xylene and mounted with a coverslip.
In some experiments, monoclonal mouse anti-human CD45, anti-human CD15, anti-human cromogranin A, and anti-low molecular weight cytokeratin 8 (Dako Corporation), were used, followed by peroxidase conjugated rabbit antimouse immunoglobulin (Dako Corporation). The reaction was visualized as described above.
For immunoelectron microscopy, the tissue was immersed in Bouin's fixative and then in 1% OsO4 in 0.2 M, pH 7.4 phosphate buffer. The tissue was then dehydrated with increasing concentrations of ethanol, ending with pure acetone, and embedded in an epon-araldite mixture. Next, the immunoglobulin-gold technique was used to localize the thymulin containing structures. For this purpose, ultrathin sections were sequentially incubated with monoclonal rat anti-FTS 4F11 for 18 hrs, rabbit anti-rat immunoglobulin for 30 min, and gold conjugated anti-rabbit immunoglobulin (20 nm) (Polysciences Inc.) for 30 min. Finally, the sections were stained with uranil acetate and lead citrate and then examined in a Phillips 300 electron microscope.
RESULTS
Polyclonal and monoclonal antibodies prepared against the synthetic FTS peptide recognize the hormone in the dot immunobinding technique, and some of them recognize thymulin in situ in the thymus gland
All the polyclonal antibodies obtained after immunization of rats with the peptide FTS reacted with thymic structures in a similar way. However, with the monoclonal antibodies, not all hybridomas whose supernatant gave a positive reaction against the synthetic thymic peptide through the dot immunobinding technique were able to detect thymulin in human thymus tissue. The most efficient monoclonal antibody obtained was produced from the 4F11 hybridoma. This hybridoma secretes rat IgM antibody that labels the same structures as the polyclonal antibodies. To study the distribution and the appearance of the cells that contain thymulin, sections of human thymic gland sections were examined. It is clear that both the monoclonal antibody 4F11 and polyclonal antibody prepared against FTS bind to thymus reticulo-epithelial cells. These cells are found in the thymus medullar area and at the peripheral layers of Hassall´s corpuscles. In addition, in all cases, a strongly stained large round cell (20-30 mm diameter) that we designated as the "C1 cell" was present (Fig. 1) .
Binding capacity of antibody 4F11 with its antigen is abrogated after incubation with thymulin or serum from young animals
In order to further test the specificity of our anti-FTS monoclonal antibody 4F11, 1 ml of the supernatant of clone 4F11 was incubated with 100 ng of thymulin or 1 mL of young mice serum. The results showed that in both cases, the binding capacity of antibody 4F11 to nitrocellulose membrane containing the conjugated peptide or to human thymus tissue sections was completely abrogated.
Characterization of the thymulin-positive "C1" cell
Reticulo-epithelial cells and Hassall´s corpuscles were also labeled with anti-keratin antibodies, confirming their epithelial nature. However, the C1 cell, which reacts strongly with all polyclonal and monoclonal anti-thymulin antibodies tested, does not bind anti-keratin antibodies and is negative for CD-45 (Fig. 2) . Therefore, the C1 cell appears to not be from an epithelial or leukocyte origin. This cell type was also negative for chromagranine A, a member of the secretogranin/chromoganin class of proteins that are frequently present in a wide variety of neurons and endocrine cells. Additionally, the C1 cell did not react with antibodies against neuron-specific enolase, ruling out a possible endocrine or neural origin.
Ultrastructural examination of the C1 cell
To further study the C1 cell, thin sections of mice thymus were prepared and immunostained with antibody 4F11. The C1 cell shows cytoplasmatic granules where the 4F11 reactive molecule is located (Fig. 3) . This observation was corroborated by an ultrastructural study in which ultrathin sections of the thymus gland were incubated with the 4F11 antibody followed by gold-labeled rabbit anti-rat immunoglobulin. The results show that the anti-thymulin monoclonal antibody recognizes and binds to electrodense cytoplasmic granules (Fig. 3, insert) .
In old mice lacking circulating thymulin, C1 cells are present at a higher density in the thymus
Interestingly, thymi of old mice without detectable levels of circulating thymulin show the presence of C1 thymulinpositive cells (Fig. 4) . A low magnification section of a young mouse thymus shows the C1 cell with a distribution in the medullar or cortico-medullar area (A). In contrast, in the old thymus where the thymic cortex is absent, increased numbers of the C1 cells are distributed in the whole tissue section (B).
Presence of the thymulin-positive C1 cell in the spleen and lymph nodes of normal mice as well as in lymphoid organs of athymic mice
A cell with characteristics similar to the thymic C1 cell may be found in spleen and lymph nodes. In the spleen it appears irregularly distributed, usually in small groups in the white pulp, and in the lymph node it can be found in the paracortical zone, among the lymphoid follicles, and in the medullar cords. In figure 5 we show spleen and lymph node sections of a normal two-month-old mouse stained with antibody 4F11, followed by mouse anti-rat immunoglobulin and PAP complex. To our surprise, similar cells appear when spleen or lymph nodes from nude or SCID mice were tested with the 4F11 antibody (Fig. 6) 
DISCUSSION
As we have reported here, not all the monoclonal antibodies prepared in our laboratory react against the FTS in the dot assay, recognize thymulin in situ. This may be due to several causes that are not mutually exclusive, for example, the binding process of the peptide with the carrier used in immunization or in the dot detection system may change its spatial molecular configuration. Other possible causes of the spatial molecular changes in the peptide are the multiple possibilities of combinations that this peptide can have with different metals and the different peptide/metal ratio binding that, as has been described, change the molecular conformation of the peptide, its antigenicity, and biological activity (Gastinel et al., 1984; Dardenne et al., 1982; Cung et al., 1988) . This raises the possibility that we are not dealing with one molecule of active hormone but with several related molecular entities. To make the scenario even more complex, the molecules that we are dealing with may have different biological functions. The selected monoclonal antibodies prepared here were able to recognize the antigen coupled to different carriers (results not shown) or thymulin in situ, as did polyclonal antibodies. One of these monoclonals is the 4F11 antibody, which was tested in several ways for specificity and was selected for its capacity to recognize the synthetic peptide coupled to BSA and bind with nitrocellulose membrane and in situ in human thymus sections. These capacities disappeared when it was incubated with a commercial synthetic peptide or mouse serum. In this case, the activity of the antibody was efficiently absorbed by serum obtained from young healthy mice, and to our surprise, was also absorbed by sera from old or thymectomized mice, although with less efficiency, indicating that some molecule crossreacting with thymulin or thymulin itself is present in low quantities in these animals. We have to remember that sera of old and thymectomized mice are negative to the Rosette test, which is the classical way to evaluate this thymic hormone. On the other hand, we can assume that the specificity of this antibody is thymulin, since it can abrogate the capacity of young serum to give a positive result to the Rosettte test (results not shown). In the thymus, it is clear that antibody 4F11 and the polyclonal antibodies prepared in our laboratory, label at least three structures: endothelialreticular cells, Hassall´s corpuscles and the C1 cells. The first two structures can easily be identified by classical histology, as well as by the fact that both react with antibodies against keratin. The case of the C1 cell, described in the Results Section, is different in that it does not bind anti-keratin antibodies. One interpretation of this is that this cell does not belong to the endodermic reticulo-epithelial cells that constitute the thymus stroma. Another explanation for the lack of reactivity with anti-keratin immunoglobulins is that this cell belongs to reticulo-epithelial cells that at a given stage of the cell cycle are deprived of keratin antigen. The latter explanation is difficult to accept since, as we show also here, these cells are present in lymphoid peripheral tissue, even in athymic mice. At an ultra structural level, the C1 positive cell contains large granules that are not normally present in reticular thymic cells. Unfortunately, Bouin is the best fixative to preserve the antigenicity of thymulin in our hands, but it is poor for maintaining the integrity of the tissue at the ultrastructural level, which makes further ultrastructural studies difficult.
Another aspect shown here that has not been reported in the literature is that in aged animals we found normal reactivity of thymic reticulo-epithelial cells with polyclonal and the monoclonal antibody 4F11. Moreover, we show here an important increase in the number of C1 cells in the old thymus, which could be due to a concentration of this cell as result of the involution of the lymphoid part of the thymic gland. Surprisingly, the C1-containing thymulin cell was also found in thymus dependent areas of spleen and lymph nodes. This is also contrary to the findings of Dardenne´s group (Berrih, 1984) and contrary to the dogma that says that thymulin is "exclusively produced in the thymus gland" (Dardenne et al., 1974) . In relation to this, we cannot rule out the possibility that these C1-like peripheral cells may only be "storing" this thymic peptide. On the other hand, other authors have already described the existence of peripheral cells that bind anti-thymulin antibodies, Kato, for example, showed that epithelial cells react in the periphery with antithymulin immunoglobulins (1982) . The hypothetic thymulin storing role of this peripheral C1-like cell is hard to accept after observing that the spleen and lymph node of athymic nude mice also present these cells, opening the possibility that thymulin can be produced in the periphery, and that even in small quantities, may contribute to peripheral T cell differentiation, as has been suggested before (Dardenne et al.,1978; Incefy et al., 1980) . This possibility is reinforced by preliminary results not shown here, where we found an abnormally high number of this cell in the lymph node of a mycosis fungoide patient. These findings almost perfectly match with the fact that the serum level of thymulin increases in this disease (Incefy et al., 1980) , giving a possible explanation for the characteristic excessive T cell proliferation. A second possible role of thymulin generated outside of thymus may be its contribution to the extrathymic T cell generation pathway that has been postulated for many years (MacDonald et al., 1981; Lawetsky et al., 1988 ) and we know now that it exists (Lake et al., 1991) , giving rise to a definitive T cell population with different attributes compared to the one generated in the classical thymic pathway (Blais et al., 2008) .
The results shown here were obtained with appropriate techniques to avoid possible false positives, and with tissue samples that facilitate the interpretation of the results. Because the majority of the tissue used in the histology studies was obtained from mice and the antibodies against thymulin were obtained from rats, the use of a second commercial antibody against rat immunoglobulin prepared in goat or rabbit is likely to react against mouse immunoglobulins, giving positively labeled B cells. To avoid this inconvenience, we prepared mouse immune serum against rat immunoglobulin, which was used as a second antibody followed by monoclonal rat PAP already described elsewhere (Villegas et al., 1991) . On the other hand, for in situ tests of monoclonal antibodies secreted by the different clones, we used sections of human thymus since mice and other experimental animals lack well-developed thymic Hassall´s corpuscles, a classical structure that is known to bind anti-thymulin antibodies (Jambon et al., 1981) .
In summary, our results show that the thymic peptide originally described by Bach may adopt different molecular configurations with different antigenic characteristics and possibly different biological activities. Additionally, thymulin appears to be produced, or at least stored, outside the thymus. We are aware that some of these results are contrary to the classical literature, but as Professor Hoecker said, "once you are sure of your data, you must publish it is no matter the reaction of the scientific community." In any case, we offer our antibody 4F11 to interested researchers.
